This morning's front pages are dominated by the hopeful news that a vaccine being developed by Pfizer could be more than 90 per cent effective,
Nphet members described the drug giant’s announcement, based on limited data from phase 3 trials, as a “good first step”, but said they awaited more detailed information being published.